Press release
Nivolumab Market Report 2024: Strategies And Recent Developments | Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc.
Nivolumab Market Characteristics
The Business Research Company offers in-depth market insights through Nivolumab Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.
Market Size And Growth Forecast:
The nivolumab market size has grown rapidly in recent years. It will grow from $1.47 billion in 2023 to $1.69 billion in 2024 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to immunotherapy advancements, increased incidence of cancer, clinical trial success, regulatory approvals.
The nivolumab market size is expected to see rapid growth in the next few years. It will grow to $2.81 billion in 2028 at a compound annual growth rate (CAGR) of 13.6%. The growth in the forecast period can be attributed to personalized medicine, emerging indications, global access to cancer care, advancements in combination therapies. Major trends in the forecast period include biomarker-driven treatment, neoantigen vaccines, enhanced immunotherapy regimens, long-term follow-up studies.
Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=13012&type=smp
Market Segmentation:
The main types of nivolumab are injection 4ml and injection 10ml. Nivolumab 40 mg/4 mL (10 mg/mL) solution is available in a single-use vial. This formulation is used for the treatment of melanoma, non-small cell lung cancer (NSCLC) and Hodgkin lymphoma. It is administered through intravenous and other routes for melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, classical Hodgkin lymphoma (CHL), squamous cell carcinoma of the head and neck (SCCHN), renal cell carcinoma (RCC) and others. It is used by clinic, hospital and others.
Major Driver - Elevated Cancer Prevalence Fuels Expansion Of The Nivolumab Market
The rising prevalence of cancer is expected to propel the growth of the nivolumab market going forward. Cancer is a category of illnesses that can develop in nearly any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their usual boundaries and either spread to other organs or invade neighboring body parts. Nivolumab is used to manage and treat several types of cancer by keeping cancer cells from suppressing the immune system and allowing the immune system to attack and kill the cancer cells. For instance, in 2023, according to the American Cancer Society Inc., a US-based non-profit health group, 1.9 million new cancer cases are expected to be diagnosed in the US, an increase compared to more than 1.8 million new cancer cases diagnosed in 2020. Therefore, the rising prevalence of cancer is driving the growth of the nivolumab market.
Competitive Landscape:
Major players in the nivolumab market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ono Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Nippon Kayaku Co. Ltd., Luye Pharma AG, Genentech Inc., Taiho Pharmaceutical Co. Ltd., SymBio Pharmaceuticals Ltd., Xbrane Biopharma AB, NeuClone Therapeutics Inc.
Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/nivolumab-global-market-report
Top Trend - Innovative Drug Development Shapes The Future Of The Nivolumab Market
Major Companies operating in the nivolumab market are focusing on developing innovative drugs to treat their customers and sustain their position in the market. The development of new drugs can improve treatment outcomes for patients with various diseases. For instance, in May 2022, Bristol-Myers Squibb Co., a US-based pharmaceutical company primarily focusing on cancer, cardiovascular, immunology and fibrotic therapeutic projects, announced that the U.S. Food and Drug Administration (FDA) had approved two nivolumab-based regimens, such as Nivolumab in combination with fluoropyrimidine and platinum-containing chemotherapy and Nivolumab plus Yervoy (ipilimumab), for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) regardless of PD-L1 status.
The Table Of Content For The Market Report Include:
1. Executive Summary
2. Nivolumab Market Characteristics
3. Nivolumab Market Trends And Strategies
4. Nivolumab Market - Macro Economic Scenario
5. Nivolumab Market Size And Growth
…..
27. Nivolumab Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Nivolumab Market Report 2024: Strategies And Recent Developments | Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc. here
News-ID: 3404475 • Views: …
More Releases from The Business research company
Evolving Market Trends In The Integrated Geophysical Services Industry: Enhancin …
The Integrated Geophysical Services Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Integrated Geophysical Services Market Size During the Forecast Period?
The integrated geophysical services market has experienced consistent growth in recent years, expected to rise from $2.35 billion in 2024 to…
Global HR Advisory Services Market: Key Trends, Market Share, Growth Drivers, An …
The HR advisory services market report describes and explains the HR advisory services market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global HR advisory services market reached a value of nearly $155.74 billion in 2024, having grown at a compound annual growth rate (CAGR) of 4.22% since…
High Voltage Aluminium Electrolytic Capacitors Global Market Report 2025: Size, …
The high voltage aluminum electrolytic capacitors report describes and explains the high voltage aluminum electrolytic capacitors market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global high voltage aluminum electrolytic capacitors market reached a value of nearly $4.10301 billion in 2024, having grown at a compound annual growth…
Global Vertical Market Software Market: Key Trends, Market Share, Growth Drivers …
The vertical market software report describes and explains the vertical market software market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global vertical market software market reached a value of nearly $152.61027 billion in 2024, having grown at a compound annual growth rate (CAGR) of 12.11% since 2019.…
More Releases for Nivolumab
Nivolumab Market Forecast 2025-2034: Comprehensive Analysis And Growth Opportuni …
The Nivolumab Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Nivolumab Market?
In the past few years, the market size for nivolumab has seen quick expansion. The market is project to increase from $1.69 billion in 2024 to $1.94…
Nivolumab Market Size, Production, Growth Segments, Business Growth Opportunitie …
The Nivolumab Market Is Set To Grow At An Estimated CAGR Of 6.8% From 2025 To 2034, Rising From $6.5 Billion In 2024 To $12.8 Billion By 2034.
On April 29, 2025, Exactitude Consultancy., Ltd. released a research report titled "Nivolumab Market" This report offers a new perspective on the Nivolumab Market covering an extensive range of aspects including market overview, expenditure analysis, import trends, segmentation, key players, and opportunities spanning.…
Elevated Cancer Prevalence Fuels Expansion Of The Nivolumab Market Driver: Leadi …
How Are the key drivers contributing to the expansion of the nivolumab market?
The nivolumab market is likely to see significant growth due to the increasing instances of cancer. Cancer, a category of diseases that can affect virtually any organ or tissue in the body, is triggered when rogue cells grow uncontrollably, disregarding their established boundaries and invading or spreading to other parts of the body. Nivolumab, a medication used to…
Nivolumab Market expected to reach USD 2,736.83 million by 2030
This Nivolumab market report has been prepared by considering several fragments of the present and upcoming market scenario. The market insights gained through this market research analysis report facilitates more clear understanding of the market landscape, issues that may interrupt in the future, and ways to position definite brand excellently. It consists of most-detailed market segmentation, thorough analysis of major market players, trends in consumer and supply chain dynamics, and…
Nivolumab Market Share, Industry Analysis And Forecast 2033
The new report published by The Business Research Company, titled Nivolumab Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the nivolumab market size has grown rapidly in recent years. It will grow from $1.47 billion in 2023 to $1.69…
Nivolumab Global Market Analysis, Trends, Growth, Research And Forecast 2033
The nivolumab market size has grown rapidly in recent years. It will grow from $1.47 billion in 2023 to $1.69 billion in 2024 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to immunotherapy advancements, increased incidence of cancer, clinical trial success, regulatory approvals.
The nivolumab market size is expected to see rapid growth in the next few years. It…
